Human FAP Protein, His Tag, active dimer (MALS verified)
分子別名(Synonym)
FAP,FAPalpha,SIMP,Seprase,APCE
表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)
Human FAP, His Tag (FAP-H5244) is expressed from human 293 cells (HEK293). It contains AA Leu 26 - Asp 760 (Accession # Q12884-1).
Predicted N-terminus: His
蛋白結(jié)構(gòu)(Molecular Characterization)
This protein carries a polyhistidine tag at the N-terminus.
The protein has a calculated MW of 86.9 kDa. The protein migrates as 95 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
內(nèi)毒素(Endotoxin)
Less than 0.1 EU per μg by the LAL method.
純度(Purity)
>95% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(chǔ)(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景(Background)
FAP(也稱(chēng)為seprase)是一種II型跨膜絲氨酸蛋白酶。質(zhì)膜和可溶性形式都表現(xiàn)出脯氨酸切割后的內(nèi)肽酶活性,對(duì)Ala/Ser-Gly-Pro-Ser/Asn/Ala共有序列有顯著的偏好。還可降解明膠,使I型膠原熱變性。還具有二肽基肽酶活性,優(yōu)選Ala-Pro、Ile-Pro、Gly-Pro、Arg-Pro和Pro-Pro。質(zhì)膜形式與DPP4、PLAUR或整合素結(jié)合,參與細(xì)胞外基質(zhì)(ECM)的細(xì)胞周蛋白水解,從而促進(jìn)細(xì)胞通過(guò)ECM的粘附、遷移和侵襲。通過(guò)降解蛋白聚糖短肽促進(jìn)神經(jīng)膠質(zhì)瘤細(xì)胞通過(guò)腦實(shí)質(zhì)的侵襲。通過(guò)以絲氨酸蛋白酶活性獨(dú)立的方式調(diào)節(jié)細(xì)胞增殖和存活,在黑素細(xì)胞中充當(dāng)腫瘤抑制因子。
關(guān)鍵字: FAP;FAP蛋白;FAP重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國(guó)生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國(guó)、美國(guó)、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶(hù)超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長(zhǎng)期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。